NCT04833881|Unknown
Loading search results
Sponsor study identifier
observational
100
1 country
1
Study Start
April 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Pregnancy-induced hypertension is a unique abnormal blood pressure disease in women during pregnancy, including eclampsia, preeclampsia, pregnancy-induced hypertension, chronic hypertension and so on. Eclampsia can lead to convulsions, proteinuria, multiple organ failure, and eventually death. It is a very serious disease in women, and the incidence of pregnancy-induced hypertension during pregnancy is between 4% and 10%. The incidence of eclampsia ranges from 2% to 5%. Studies have shown that there are about 60,000 cases of stillbirth or stillbirth due to eclampsia every year worldwide. At present, there are many theories about the pathogenesis of eclampsia, such as oxidative stress theory, maternal and fetal interaction theory, immune imbalance theory, heredity theory and so on.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 11, 2021
Actual (reported)April 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
April 6, 2021
Actual (reported)November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Proteomics and acetylation modification analysis of placenta, blood, urine, and cervical secretions
Proteomics analysis is carried out using the TMT labeling quantitative method, the significantly differentially expressed proteins and modification sites are screened out, and then the proteins with significantly different changes are used as disease signs; Through the GO classification analysis of the protein, the subcellular structure location analysis of the protein is carried out, and the mitochondrial-related protein and skeleton protein are concerned. Through the enrichment of acetylated antibody modified protein-peptide, the changes of modified protein and its regulatory mechanism were analyzed, and the regulatory role of acetylated protein in mitochondrial metabolism and immune response was found. This study uses the Mfuzz clustering method to perform clustering analysis of the expression profile of proteins, the pathogenesis of the disease through protein enrichment analysis, pathway analysis, and interaction analysis are explored.
2023-08
1\. Women with preeclampsia: 1. Singleton women who meet the diagnostic criteria for preeclampsia. 2. No previous history of major disease. 3. Body mass index is between 23-25kg/m2. 4. 20-45 years old. 5. 22-42 weeks of gestation. 6. Participate in the test voluntarily and sign the informed consent. 2\. Healthy pregnant women: 1. In good health, no history of major diseases before pregnancy, pregnant women and single mothers with healthy fetuses (newborn) after pregnancy and delivery. 2. Body mass index is between 23-25kg/m2. 3. 20-45 years old. 4. 22-42 weeks of gestation. 5. Participate in the test voluntarily and sign the informed consent.
The First Affiliated Hospital of Heilongjiang University of Chinese Medicine
Harbin, Heilongjiang, 150000, China
First Submitted
March 11, 2021
First Posted
April 6, 2021
Study Start
April 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
Contact the study team to confirm eligibility.
November 2024
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 6, 2021
Record last verified: 2021-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: